Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Disrupted biological function, manifesting through the hallmarks of aging, poses one of the largest threats to healthspan and risk of disease development, such as metabolic disorders, cardiovascular ailments, and neurodegeneration. In recent years, numerous geroprotectors, senolytics, and other nutraceuticals have emerged as potential disruptors of aging and may be viable interventions in the immediate state of human longevity science. In this review, we focus on the decrease in nicotinamide adenine dinucleotide (NAD+) with age and the supplementation of NAD+ precursors, such as nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), in combination with other geroprotective compounds, to restore NAD+ levels present in youth. Furthermore, these geroprotectors may enhance the efficacy of NMN supplementation while concurrently providing their own numerous health benefits. By analyzing the prevention of NAD+ degradation through the inhibition of CD38 or supporting protective downstream agents of SIRT1, we provide a potential framework of the CD38/NAD+/SIRT1 axis through which geroprotectors may enhance the efficacy of NAD+ precursor supplementation and reduce the risk of age-related diseases, thereby potentiating healthspan in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ageing as a Risk Factor for Disease
Niccoli, T., & Partridge, L. (2012) · Current Biology · doi:10.1016/j.cub.2012.07.024 · Cited by 1,831
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Gomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
Yoshino, J., Baur, J. A., & Imai, S.-I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.002 · Cited by 1,061 · cited 1×
“NAD+ precursors, such as NR, NMN, and NAM, have been implicated in the adequate uptake and subsequent biosynthesis of NAD+ [66,67].”
BackgroundFisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032 · cited 1×
“Administration of fisetin improved lifespan and tissue homeostasis in mice [156].”
BackgroundCamacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.006 · Cited by 901
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834 · cited 1×
“but despite this lack of clarity in interventional disease trials, resveratrol might still be considered an age-related metabolic modulator [104].”
BackgroundLuen Tang, B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2318 · Cited by 740 · cited 6×
“The activation of SIRT1 along with AMPK and PGC1α in response to resveratrol is implicated, Nutrients 2023, 15, 445 8 of 23 but despite this lack of clarity in interventional disease trials, resveratrol might still be considered an age-related metabolic modulator [104].”
BackgroundInfluentialNAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627 · cited 1×
“NAD+ can be synthesized de novo from nicotinic acid (NA), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) or can be salvaged through the NAD+ salvage pathway, which is crucial for recycling the metabolites of biochemical reactions to replete NAD+ stores in the body [20].”
BackgroundResveratrol and health—A comprehensive review of human clinical trials
Smoliga, J. M., Baur, J. A., & Hausenblas, H. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100143 · Cited by 594
SARM1 activation triggers axon degeneration locally via NAD + destruction
Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A., & Milbrandt, J. (2015) · Science · doi:10.1126/science.1258366 · Cited by 593
Barger, J. L., Kayo, T., Vann, J. M., Arias, E. B., Wang, J., Hacker, T. A., Wang, Y., Raederstorff, D., Morrow, J. D., Leeuwenburgh, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002264 · Cited by 580
NAD(+) in aging: molecular mechanisms and translational implications
Fang, E. F., Lautrup, S., Hou, Y., Demarest, T. G., Croteau, D. L., Mattson, M. P., & Bohr, V. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.001 · Cited by 501
Witte, A. V., Kerti, L., Margulies, D. S., & Floel, A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0385-14.2014 · Cited by 455
Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages
Covarrubias, A. J., Kale, A., Perrone, R., Lopez-Dominguez, J. A., Pisco, A. O., Kasler, H. G., Schmidt, M. S., Heckenbach, I., Kwok, R., Wiley, C. D., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00305-3 · Cited by 420
CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels
Chini, C. C. S., Peclat, T. R., Warner, G. M., Kashyap, S., Espindola-Netto, J. M., de Oliveira, G. C., Gomez, L. S., Hogan, K. A., Tarragó, M. G., Puranik, A. S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00298-z · Cited by 349
NAD+-Dependent Activation of Sirt1 Corrects the Phenotype in a Mouse Model of Mitochondrial Disease
Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A. A., Li, W., Leoni, V., Schon, E. A., Dantzer, F., Auwerx, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.001 · Cited by 343 · cited 1×
“In mitochondrial disease models, PARP inhibition or NR supplementation ameliorated deficits in metabolism and exercise capacity [56].”
BackgroundFlavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O’Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2013) · Diabetes · doi:10.2337/db12-1139 · Cited by 332 · cited 2×
“Inhibition of CD38 in obesity models led to an enhanced metabolic profile, increased NAD+ levels, and decreased protein acetylation, possibly due to enhanced SIRT1 activity due to higher NAD+ availability [160].”
BackgroundFisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., Aggarwal, V., & Sandhu, S. S. (2019) · Biomolecules · doi:10.3390/biom9050174 · Cited by 285 · cited 1×
“Fisetin and quercetin are potent anti-cancer agents and have been shown to have anti-tumor activity through calcium-induced tumor apoptosis along with improving cancerrelated inflammatory profiles [155].”
BackgroundSelf-citationNAD metabolism: Implications in aging and longevity
Yaku, K., Okabe, K., & Nakagawa, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.006 · Cited by 269
Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide
Schmeisser, K., Mansfeld, J., Kuhlow, D., Weimer, S., Priebe, S., Heiland, I., Birringer, M., Groth, M., Segref, A., Kanfi, Y., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1352 · Cited by 236 · cited 1×
“Methylnicotinamide has also been shown to increase lifespan [25].”
BackgroundNAD and the aging process: role in life, death and everything in between
Chini, C. C. S., Tarragó, M. G., & Chini, E. N. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.11.003 · Cited by 208 · cited 1×
“Administration of NAD+ precursors, namely NR and NMN, has been shown to alleviate age-related NAD+ pathology, particularly in the context of age-related diseases [13,31,32].”
BackgroundIrie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0313 · Cited by 191
Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0016-9 · Cited by 181
Clinical applications of coenzyme Q₁₀
Garrido-Maraver, J. (2014) · Frontiers in Bioscience · doi:10.2741/4231 · Cited by 178
The role of PARP1 in neurodegenerative diseases and aging
Mao, K., & Zhang, G. (2022) · The FEBS Journal · doi:10.1111/febs.15716 · Cited by 172
Chini, C., Hogan, K. A., Warner, G. M., Tarragó, M. G., Peclat, T. R., Tchkonia, T., Kirkland, J. L., & Chini, E. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.199 · Cited by 138
Why NAD + Declines during Aging: It’s Destroyed
Schultz, M. B., & Sinclair, D. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.022 · Cited by 126 · cited 1×
“NAD+ levels sharply decline with age, and this decline can be attributed to the activity of CD38, an enzyme responsible for the degradation of NAD+, which disrupts the NAD+ synthesis pathways during the course of aging [17].”
BackgroundOgura, Y., Kitada, M., Xu, J., Monno, I., & Koya, D. (2020) · Aging · doi:10.18632/aging.103410 · Cited by 118 · cited 1×
“CD38 inhibition through apigenin administration additionally restores mitochondrial function in response to oxidative stress and increases the NAD+/NADH ratio and SIRT3 activation [180].”
BackgroundNMN Maintains Intestinal Homeostasis by Regulating the Gut Microbiota
Huang, P., Jiang, A., Wang, X., Zhou, Y., Tang, W., Ren, C., Qian, X., Zhou, Z., & Gong, A. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.714604 · Cited by 110 · cited 1×
“Short term supplementation of NMN in pre-aging mice and humans, ages 45 to 60 years, showed a significant increase in telomere length in peripheral blood mononuclear cells, as well as altered fecal microbiota benefiting immune and metabolic pathways [74], where specific administration in mice has been shown to increas…”
BackgroundCoenzyme Q10: From bench to clinic in aging diseases, a translational review
Gutierrez-Mariscal, F. M., Yubero-Serrano, E. M., Villalba, J. M., & Lopez-Miranda, J. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1442316 · Cited by 92
Choi, W. H., Son, H. J., Jang, Y. J., Ahn, J., Jung, C. H., & Ha, T. Y. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700218 · Cited by 81 · cited 1×
“Apigenin supplementation has anti-obesity effects, with marked reductions in visceral adipose tissue in high-fat-fed mice, and can preserve skeletal muscle in obese mouse models of obesity-induced skeletal muscle atrophy [175,176].”
BackgroundThe Paradox of Coenzyme Q10 in Aging
Díaz-Casado, M. E., Quiles, J. L., Barriocanal-Casado, E., González-García, P., Battino, M., López, L. C., & Varela-López, A. (2019) · Nutrients · doi:10.3390/nu11092221 · Cited by 81 · cited 1×
“Replenishing the age-related decline in levels of CoQ10 is imperative to reduce the risk of age-related diseases and lower the burden of age-inducing oxidative stress through nutraceutical supplementation [146].”
BackgroundLuteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H)
Boslett, J., Hemann, C., Zhao, Y. J., Lee, H.-C., & Zweier, J. L. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239459 · Cited by 69
Intervening in ageing to prevent the diseases of ageing
Partridge, L. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.08.003 · Cited by 69 · cited 1×
“Each intervention is thought to focus on these hallmarks or even have a multimodal crossover effect ameliorating the biological processes of aging [4].”
BackgroundGonzález-Guardia, L., Yubero-Serrano, E. M., Delgado-Lista, J., Perez-Martinez, P., Garcia-Rios, A., Marin, C., Camargo, A., Delgado-Casado, N., Roche, H. M., Perez-Jimenez, F., et al. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu098 · Cited by 64
Li, B. S., Zhu, R. Z., Lim, S.-H., Seo, J. H., & Choi, B.-M. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500592 · Cited by 54
Liu, X., DILXAT, T., Shi, Q., Qiu, T., & Lin, J. (2022) · Gene · doi:10.1016/j.gene.2022.146348 · Cited by 34 · cited 1×
“Nrf2 was upregulated, and in vivo models showed enhanced cognition compared to NMN alone [189].”
BackgroundCros, C., Cannelle, H., Laganier, L., Grozio, A., & Canault, M. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112060 · Cited by 23 · cited 1×
“A contrasting study, however, showed no adverse effects on rats after administration of NMN at doses of 375, 750, and 150 mg/kg/d, with a maximum acute dose identified at 2666 mg/kg/d, enhancing the safety profile of NMN supplementation [81] To understand if there are differences in the safety of NAD+ precursor use, a…”
BackgroundLi, J., Zhang, Y., Zeng, X., Cheng, Y., Tang, L., Hong, D., & Yang, X. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108862 · Cited by 23
Cited by
Chronic inflammation and the hallmarks of aging
Baechle, J. J., Chen, N., Makhijani, P., Winer, S., Furman, D., & Winer, D. A. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101755 · Cited by 471
Theodorakis, N., Feretzakis, G., Tzelves, L., Paxinou, E., Hitas, C., Vamvakou, G., Verykios, V. S., & Nikolaou, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090931 · Cited by 51
“ML can analyze metabolomic profiles to identify candidates with low NAD+ levels or impaired NAD+ metabolism who may benefit from such supplementation [54].”
BackgroundTero-Vescan, A., Degens, H., Matsakas, A., Ștefănescu, R., Ősz, B. E., & Slevin, M. (2025) · Pharmaceuticals · doi:10.3390/ph18081222 · Cited by 44
Metadata
- Authors
- Sharma, A., Chabloz, S., Lapides, R. A., Roider, E., & Ewald, C. Y.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2023-01-14
- Volume
- 15
- Issue
- 2
- Pages
- 445
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W4316465812
- Cited by
- 60
- References
- 41
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.